Aadi Bioscience Inc
NASDAQ:AADI
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| US |
|
Aadi Bioscience Inc
NASDAQ:AADI
|
49.7m USD |
-55%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
361.9B USD |
3%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
156.4B USD |
7%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
148.1B USD |
12%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.3B USD |
16%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.8B AUD |
7%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.5B USD |
12%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
57.6B USD |
-7%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
Aadi Bioscience Inc
Glance View
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Aadi Bioscience Inc's most recent financial statements, the company has ROA of -54.7%.
You don't have any saved screeners yet